~ VP Market Access, Health Economics, & Reimbursement
Back in 2017, Intrinsic Therapeutics was an innovative startup focused on a pivotal clinical trial and regulatory pathways. Intrinsic had no internal go-to-market staff.
Intrinsic had a wealth of unpublished clinical data from the largest randomized control trial ever performed on discectomy patients.
So how was Intrinsic going to leverage this data to prepare for commercialization?
Working with Telos, Intrinsic put together an aggressive publication strategy to factually and comprehensively communicate the value of the Barricaid Annular Closure Device.
Telos/Intrinsic designed the appropriate sub-studies, literature reviews, and analyses to objectively answer foreseeable stakeholder or decision-maker questions in the peer-reviewed literature and on the podium at a wide variety of spine and orthopedic society conferences.
Telos helped to move the total peer-reviewed article count from 14 to 53 in just over two years.
Intrinsic was faced with the challenge that current reimbursement codes for discectomies do not involve an implant cost or the extra procedural time and steps required to implant the device.
Telos and Intrinsic laid out a plan for four separate health economics analyses based on 550 patients from the randomized controlled trial and brought all analyses to fruition: